Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion

Leuk Lymphoma. 2016 Nov;57(11):2685-8. doi: 10.3109/10428194.2016.1154955. Epub 2016 Mar 21.

Authors

Francesco Cavazzini¹, Enrico Lista¹, Francesca Maria Quaglia¹, Luca Formigaro¹, Maurizio Cavallari¹, Sara Martinelli¹, Gian Matteo Rigolin¹, Robin Foà², Antonio Cuneo¹

Affiliations

¹ a Section of Hematology, Department of Medical Sciences , University of Ferrara , Ferrara , Italy ;
² b Division of Hematology, "La Sapienza" , University of Rome , Rome , Italy.

PMID: 26999572
DOI: 10.3109/10428194.2016.1154955

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / etiology
Chromosome Deletion
Chromosomes, Human, Pair 17 / genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Male
Middle Aged
Piperidines
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Recurrence
Treatment Outcome

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine